MedPath

Vincristine

Generic Name
Vincristine
Brand Names
Marqibo, Vincasar
Drug Type
Small Molecule
Chemical Formula
C46H56N4O10
CAS Number
57-22-7
Unique Ingredient Identifier
5J49Q6B70F

Overview

Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea. It is marketed under several brand names, many of which have different formulations such as Marqibo (liposomal injection) and Vincasar. Vincristine is indicated for the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. vincristine sulfate is often chosen as part of polychemotherapy because of lack of significant bone–marrow suppression (at recommended doses) and of unique clinical toxicity (neuropathy).

Indication

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

Associated Conditions

  • Acute Lymphoblastic Leukemia (ALL)
  • Choriocarcinoma
  • Chronic Lymphocytic Leukemia
  • Ewing's Sarcoma
  • Gestational Trophoblastic Neoplasia
  • Hepatoblastomas
  • Hodgkin's Lymphoma
  • Immune Thrombocytopenia (ITP)
  • Kaposi's Sarcoma
  • Multiple Myeloma (MM)
  • Neuroblastoma (NB)
  • Non-Hodgkin's Lymphoma (NHL)
  • Ovarian germ cell tumour
  • Pheochromocytoma
  • Relapsed Acute Lymphoblastic Leukemia (ALL)
  • Retinoblastoma
  • Rhabdomyosarcomas
  • Small Cell Lung Cancer (SCLC)
  • Wilms' tumor
  • Advanced Thymoma

Research Report

Published: Jul 16, 2025

A Comprehensive Monograph on Vincristine (DB00541): Pharmacology, Clinical Utility, and Risk Management

1.0 Executive Summary

Vincristine is a complex, naturally occurring antineoplastic agent belonging to the vinca alkaloid class of chemotherapeutics. Isolated from the Madagascar periwinkle plant, Catharanthus roseus, it has been a cornerstone of cancer treatment for over half a century.[1] Its primary mechanism of action involves the disruption of microtubule dynamics, leading to cell cycle arrest in the mitotic phase and subsequent apoptosis of rapidly dividing cancer cells.[4] Vincristine demonstrates a broad spectrum of clinical activity, proving indispensable in combination chemotherapy regimens for a variety of hematologic malignancies—including acute lymphocytic leukemia (ALL) and Hodgkin and non-Hodgkin lymphomas—as well as numerous pediatric solid tumors such as Wilms' tumor, neuroblastoma, and rhabdomyosarcoma.[1]

A defining characteristic that establishes Vincristine's unique therapeutic niche is its relative lack of significant bone marrow suppression at standard doses, a property that allows it to be combined effectively with more myelosuppressive agents.[1] However, the clinical utility of Vincristine is fundamentally constrained by its significant and cumulative dose-limiting toxicity: a severe peripheral neuropathy that can manifest with sensory, motor, and autonomic dysfunction.[4] The management of patients receiving Vincristine is therefore a delicate balance between maximizing its potent anticancer effects and mitigating its debilitating neurotoxicity. Compounding these challenges is a critical and absolute safety mandate: Vincristine is for intravenous administration only. Inadvertent intrathecal injection is almost uniformly fatal, necessitating stringent, system-wide safety protocols to prevent this catastrophic medical error.[9]

2.0 Drug Identification and Formulation

2.1 Chemical Identity and Origin

Continue reading the full research report

Clinical Trials

Title
Posted
Study ID
Phase
Status
Sponsor
2025/08/21
Not Applicable
Not yet recruiting
City of Hope Medical Center
2025/07/18
Not Applicable
Not yet recruiting
2025/05/18
Phase 1
Recruiting
2025/05/02
Phase 2
Recruiting
Jennifer Amengual
2025/04/24
Early Phase 1
Not yet recruiting
C17 Council
2025/04/09
Phase 2
Not yet recruiting
City of Hope Medical Center
2025/04/04
Phase 3
Recruiting
2025/02/11
Phase 2
Not yet recruiting
2025/01/06
Phase 1
Recruiting
Sun Yat-sen University
2024/12/17
Phase 2
Not yet recruiting

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Hospira, Inc.
61703-309
INTRAVENOUS
1 mg in 1 mL
2/3/2023
Hospira, Inc.
61703-309
INTRAVENOUS
1 mg in 1 mL
2/1/2023

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
VINRACINE INJ. 1 mg/ml
SIN10319P
INJECTION
1 mg/ml
10/29/1998

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
VINCRISTINE SULFATE INJ 5MG/VIAL USP
david bull laboratories (pty) ltd.
00690317
Powder For Solution - Intravenous
5 MG / VIAL
12/31/1989
VINCRISTINE SULFATE INJ 1MG/ML USP
david bull laboratories (pty) ltd.
00726575
Liquid - Intravenous
1 MG / ML
12/31/1989
ONCOVIN SOLUTION 1MG/ML
eli lilly canada inc
00611182
Liquid - Intravenous
1 MG / ML
12/31/1984
VINCRISTINE SULFATE INJECTION
teva canada limited
02143305
Solution - Intravenous
1 MG / ML
12/31/1995
VINCRISTINE SULFATE INJECTION
02324148
Solution - Intravenous
1 MG / ML
N/A
VINCRISTINE SULFATE INJECTION USP
uman pharma inc
02333198
Solution - Intravenous
1 MG / ML
N/A
VINCRISTINE SULFATE INJECTION USP
02183013
Solution - Intravenous
1 MG / ML
8/7/1997

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.